Trial results

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815 on ClinicalTrials.gov · last registry update 2016-11-28

Finished June 2011, after enrolling 484 people. Primary outcome, as filed: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

484

Started

2008-09

Primary completion

2011-06 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.